$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000145368717000065 Filed on November 07, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$17.00K	$27.00K	$1.048M
YoY Change	-99.42%	-97.42%	-34.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.670M	$4.380M	$2.500M
YoY Change	-1.56%	75.2%	13.64%
% of Gross Profit
Research & Development	$13.62M	$9.504M	$6.021M
YoY Change	23.48%	57.85%	9.81%
% of Gross Profit
Depreciation & Amortization	$180.0K	$200.0K	$100.0K
YoY Change	-28.0%	100.0%	-50.0%
% of Gross Profit
Operating Expenses	$19.29M	$13.88M	$8.516M
YoY Change	14.91%	63.0%	10.91%
Operating Profit		-$13.85M	-$7.468M
YoY Change		85.51%	23.01%
Interest Expense	-$130.0K	$268.0K	$311.0K
YoY Change	-58.06%	-13.83%	-6.89%
% of Operating Profit
Other Income/Expense, Net	-$140.0K	-$16.00K	$4.000K
YoY Change	-275.0%	-500.0%	-130.77%
Pretax Income	-$19.54M	-$14.68M	-$7.730M
YoY Change	38.78%	89.91%	34.9%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$19.54M	-$14.68M	-$7.728M
YoY Change	38.78%	89.91%	34.99%
Net Earnings / Revenue	-114964.71%	-54355.56%	-737.4%
Basic Earnings Per Share
Diluted Earnings Per Share	-$876.6K	-$664.9K	-$426.8K
COMMON SHARES
Basic Shares Outstanding	22.34M shares	22.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$96.60M	$104.4M	$79.30M
YoY Change	14.86%	31.65%
Cash & Equivalents	$70.62M	$72.15M	$59.49M
Short-Term Investments	$25.90M	$32.20M	$19.80M
Other Short-Term Assets	$2.100M	$3.000M	$3.600M
YoY Change	-16.0%	-16.67%
Inventory
Prepaid Expenses
Receivables	$63.00K	$0.00	$483.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$98.68M	$107.4M	$83.40M
YoY Change	13.67%	28.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.091M	$2.055M	$2.066M
YoY Change	2.15%	-0.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change	-100.0%
Total Long-Term Assets	$2.420M	$2.371M	$2.382M
YoY Change	-2.62%	-0.46%
TOTAL ASSETS
Total Short-Term Assets	$98.68M	$107.4M	$83.40M
Total Long-Term Assets	$2.420M	$2.371M	$2.382M
Total Assets	$101.1M	$109.7M	$85.78M
YoY Change	13.21%	27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.606M	$1.519M	$1.040M
YoY Change	-58.63%	46.06%
Accrued Expenses	$8.580M	$6.547M	$2.434M
YoY Change	118.82%	168.98%
Deferred Revenue	$787.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$2.900M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$10.97M	$11.32M	$7.690M
YoY Change	-19.94%	47.23%
LONG-TERM LIABILITIES
Long-Term Debt	$21.00M	$21.00M	$9.100M
YoY Change	162.5%	130.77%
Other Long-Term Liabilities	$1.201M	$1.250M	$0.00
YoY Change
Total Long-Term Liabilities	$1.201M	$1.250M	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.97M	$11.32M	$7.690M
Total Long-Term Liabilities	$1.201M	$1.250M	$0.00
Total Liabilities	$49.29M	$44.65M	$20.34M
YoY Change	43.51%	119.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$216.9M	-$197.4M	-$137.5M
YoY Change	43.07%	43.54%
Common Stock	$3.000K	$2.000K	$1.000K
YoY Change	200.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$51.81M	$65.08M	$65.44M
YoY Change
Total Liabilities & Shareholders Equity	$101.1M	$109.7M	$85.78M
YoY Change	13.21%	27.91%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$19.54M	-$14.68M	-$7.728M
YoY Change	38.78%	89.91%	34.99%
Depreciation, Depletion And Amortization	$180.0K	$200.0K	$100.0K
YoY Change	-28.0%	100.0%	-50.0%
Cash From Operating Activities	-$12.67M	-$15.44M	-$5.470M
YoY Change	-912.18%	182.27%	-2.5%
INVESTING ACTIVITIES
Capital Expenditures	-$150.0K	-$120.0K	-$280.0K
YoY Change	36.36%	-57.14%	-41.67%
Acquisitions
YoY Change
Other Investing Activities	$6.250M	-$2.240M	-$19.94M
YoY Change	-222.79%	-88.77%	2594.59%
Cash From Investing Activities	$6.110M	-$2.380M	-$20.21M
YoY Change	-217.5%	-88.22%	1556.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.030M	7.340M	2.360M
YoY Change	80.29%	211.02%	-92.62%
NET CHANGE
Cash From Operating Activities	-12.67M	-15.44M	-5.470M
Cash From Investing Activities	6.110M	-2.380M	-20.21M
Cash From Financing Activities	5.030M	7.340M	2.360M
Net Change In Cash	-1.530M	-10.48M	-23.32M
YoY Change	80.0%	-55.06%	-192.72%
FREE CASH FLOW
Cash From Operating Activities	-$12.67M	-$15.44M	-$5.470M
Capital Expenditures	-$150.0K	-$120.0K	-$280.0K
Free Cash Flow	-$12.52M	-$15.32M	-$5.190M
YoY Change	-849.7%	195.18%	1.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22336576	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2016Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	420000	USD
CY2017Q3	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	204000	USD
CY2016Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	170000	USD
CY2017Q3	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1239000	USD
CY2016Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	152000	USD
CY2017Q3	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2016Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	245000	USD
CY2017Q3	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	284000	USD
CY2016Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	29000	USD
CY2017Q3	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	67000	USD
CY2016Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	794000	USD
CY2017Q3	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	2054000	USD
	selb	Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger	300000	USD
	selb	Debt Instrument Event Of Default Minimum Assets Trigger DebtInstrumentEventOfDefaultMinimumAssetsTrigger	300000	USD
CY2016Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	300000	USD
CY2017Q3	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-207000	USD
	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	0	USD
	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	29000	USD
	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	4369000	USD
	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
	selb	Proceeds From Vesting Of Restricted Stock ProceedsFromVestingOfRestrictedStock	16000	USD
	selb	Proceeds From Vesting Of Restricted Stock ProceedsFromVestingOfRestrictedStock	0	USD
	selb	Stock Issued During Period Value Conversion Preferred Stock Warrants StockIssuedDuringPeriodValueConversionPreferredStockWarrants	47115000	USD
CY2017Q3	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3882000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1519000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	215000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-113000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-200000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3921000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6547000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3740000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4079000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4518000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4409000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211125000	USD
CY2017Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	266836000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2872000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1281000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2872000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2254090	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2595972	shares
CY2016Q4	us-gaap	Assets Assets	89301000	USD
CY2017Q3	us-gaap	Assets Assets	109723000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	86816000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	107352000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	24785000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	32237000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24821000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	32241000	USD
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	28000000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24821000	USD
CY2017Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	32241000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24785000	USD
CY2017Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	32237000	USD
CY2017Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	22	position
CY2017Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	25	position
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	8000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32337000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59488000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58656000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	72151000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	27151000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	13495000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3164965	shares
CY2017Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3905215	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18438742	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22120507	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18438742	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22120507	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7697000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21695000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14672000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45668000	USD
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	10126118	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	222000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	168000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1836000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3256000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12439000	USD
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	10953000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	100000	USD
	us-gaap	Depreciation Depreciation	545000	USD
	us-gaap	Depreciation Depreciation	500000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Depreciation Depreciation	567000	USD
	us-gaap	Depreciation Depreciation	600000	USD
	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.39
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.31
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	419000	USD
CY2017Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-673000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-673000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2495000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7294000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4377000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13155000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-35000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	34344000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	80000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1551000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1976000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-51000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-429000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-30000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-113000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-16000	USD
CY2016Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2399000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-341000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-215000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-763000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3768000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	586000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-66000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1668000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	386000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-507000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-703000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	311000	USD
	us-gaap	Interest Expense InterestExpense	931000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	268000	USD
	us-gaap	Interest Expense InterestExpense	847000	USD
	us-gaap	Interest Paid InterestPaid	729000	USD
	us-gaap	Interest Paid InterestPaid	660000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81000	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	47000	USD
CY2016Q3	us-gaap	Investment Income Net InvestmentIncomeNet	98000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	121000	USD
CY2017Q3	us-gaap	Investment Income Net InvestmentIncomeNet	165000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	379000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	44647000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89301000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109723000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13706000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11322000	USD
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	4067000	USD
CY2017Q3	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	7977000	USD
CY2017Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	20954000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	16000	USD
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	31000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	64867000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60985000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16896000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8205000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21239000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39365000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-7728000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22127000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-14676000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45777000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7728000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26693000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14676000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-45777000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	8516000	USD
	us-gaap	Operating Expenses OperatingExpenses	25963000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	13881000	USD
	us-gaap	Operating Expenses OperatingExpenses	44697000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-7468000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20810000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13854000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44507000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4200000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1244000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	335000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1330000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1291000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	400000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1400000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	479000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	501000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2016Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	15000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	416000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	79000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1250000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	16000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	30000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	176000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	249000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4068000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	478000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	584000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	23318000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48736000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2382000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2888000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	68871000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	47120000	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	20999000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	6900000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	41115000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	48000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	620000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	180000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5787000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6134000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2047000	USD
	us-gaap	Revenues Revenues	5153000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2055000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	75000	USD
CY2017Q3	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12934000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6021000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18669000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9504000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31542000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	78000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	76000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2017Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151576000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151600000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197400000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-197353000	USD
CY2016Q3	us-gaap	Revenues Revenues	1048000	USD
CY2017Q3	us-gaap	Revenues Revenues	27000	USD
	us-gaap	Revenues Revenues	190000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22120507	shares
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	25485000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	32237000	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	180000	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	5000000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	620000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	54957000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	65076000	USD
CY2016Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	3.9
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4566000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2016Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4566000	USD
CY2017Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	28804969	shares
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	37835623	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18108014	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7881625	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22082207	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19803551	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> in Russian bank accounts, of which </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> was held in U.S. dollars.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has minimal credit risk as the majority of accounts receivable relates to amounts due under a government sponsored grant, collaboration with large pharmaceutical companies or grants from well‑known and supported non‑profit organizations. The Company did not have any off balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation, income taxes, collectability of accounts receivable, useful lives of long-lived assets, accrued expenses, and accounting for project development. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s management made significant estimates and assumptions in determining the fair value of its common stock for those periods reported prior to the completion of the initial public offering of the Company’s common stock (the “IPO”). The Company utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that require the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of its preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</font></div></div>

Files In Submission

Name	View Source	Status
0001453687-17-000065-index-headers.html	Edgar Link	pending
0001453687-17-000065-index.html	Edgar Link	pending
0001453687-17-000065.txt	Edgar Link	pending
0001453687-17-000065-xbrl.zip	Edgar Link	pending
exhibit102_cfoemploymentag.htm	Edgar Link	pending
exhibit103_ccoemploymentag.htm	Edgar Link	pending
exhibit311_93017.htm	Edgar Link	pending
exhibit312_93017.htm	Edgar Link	pending
exhibit321_93017.htm	Edgar Link	pending
exhibit322_93017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20170930.xml	Edgar Link	completed
selb-20170930.xsd	Edgar Link	pending
selb-20170930_cal.xml	Edgar Link	unprocessable
selb-20170930_def.xml	Edgar Link	unprocessable
selb-20170930_lab.xml	Edgar Link	unprocessable
selb-20170930_pre.xml	Edgar Link	unprocessable
selectabiosciences10-q93017.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2017 Q4 Form 10-Q Financial Statement

#000145368717000065 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2017 Q4 Form 10-Q Financial Statement

#000145368717000065 Filed on November 07, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac